You are here

Therapy for drug resistant influenza strains by nucleic acid targeting of respiratory airways

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R41AI124851-01A1
Agency Tracking Number: R41AI124851
Amount: $349,900.00
Phase: Phase I
Program: STTR
Solicitation Topic Code: NIAID
Solicitation Number: PA15-270
Solicitation Year: 2015
Award Year: 2016
Award Start Date (Proposal Award Date): 2016-07-02
Award End Date (Contract End Date): 2018-06-30
Small Business Information
Buffalo, NY 14260-4200
United States
DUNS: 079940923
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 (716) 213-8414
Business Contact
Phone: (716) 213-8414
Research Institution
AMHERST, NY 14228-2567
United States

 Nonprofit College or University

Antiviral drugs are a crucial countermeasure for influenza A virus IAV particularly in circumstances of
increased IAV incidence or if a vaccine is unavailable e g virulent H N IAV However the emergence of IAV
strains that are resistant to current antivirals H N underscores the need for new treatment strategies
particularly those that modify the host response IAVs infect of the US population with andgt
hospitalizations and deaths annually Morbidity and mortality are secondary to an intense systemic
stress to the antiviral immune response particularly in those individuals with co morbidities i e chronic
respiratory and cardiovascular diseases Additionally endemic IAV strains from other species e g H N can
kill healthy individuals by a cytokine storm The emergence of pandemic strains is inevitable as seen most
recently with H N Moreover IAV s ability to rapidly acquire increased virulence and efficient human to
human transmission through genetic shift is a constant threat to the global population and benign strains may
rapidly evolve and cause severe morbidity and mortality This application proposes to develop for use in patients
a novel therapeutic gene knockdown strategy localized to respiratory epithelium by employing nanoplexes an
electrostatic complex of cationic polymers and anionic nucleic acids Our preliminary findings have demonstrated
that this antiviral therapy inhibits IAV replication decreases IAV induced lung injury and improves antibacterial
host responses This Phase I STTR application will optimize the fabrication and delivery of the nanoplexes and
establish its in vitro efficacy with respect to antiviral and IFN I stimulating activity and toxicity The subsequent
Phase II STTR application will determine its in vivo efficacy and toxicity in mice and ferrets utilizing drug resistant
laboratory epidemic pandemic and pathogenic strains PROJECT NARRATIVE
The proposed STTR Phase I project will test the effectiveness of RNA delivery for therapeutic applications in
influenza treatment Success will be the basis for a Phase II application dedicated to expanded assessment and
scaled production of a potential new therapy for influenza

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government